<https://rdf.molmedb.upol.cz/reference/ref4132> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane19>;
	<http://purl.org/ontology/bibo/doi> "10.1016/j.bmcl.2018.03.045"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/pmid> "29588215"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494313>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM494189>,
		<https://identifiers.org/molmedb/MM494193>,
		<https://rdf.molmedb.upol.cz/interaction/method30>;
	<http://purl.org/dc/terms/bibliographicCitation> "Ding X, Stasi LP, Ho MH, Zhao B, Wang H, Long K, Xu Q, Sang Y, Sun C, Hu H, Yu H, Wan Z, Wang L, Edge C, Liu Q, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F.: Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorg Med Chem Lett, Volume 28 (9), 2018"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1018247> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4132> .
<https://rdf.molmedb.upol.cz/interaction/int1018609> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4132> .
<https://rdf.molmedb.upol.cz/interaction/int1018165> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref4132> .